Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens. (Q36682418)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Bonnie B Plikaytis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Thomas M Shinnick

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

language of work or name

English

0 references

publication date

15 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

1553-1566

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17166640%20AND%20SRC:MED&resulttype=core&format=json

TB vaccines: progress and problems.

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Diagnostic test needs for evaluating antituberculosis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

T cell response to Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Human immune recognition-based multicomponent subunit vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

TB vaccines for the World

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Real world TB vaccines: clinical trials in TB-endemic regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immune response toMycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

How can immunology contribute to the control of tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Tuberculosis subunit vaccine development: on the role of interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Type 2 Cytokine Gene Activation and Its Relationship to Extent of Disease in Patients with Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

IL-4 in tuberculosis: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Responses of bovine WC1(+) gammadelta T cells to protein and nonprotein antigens of Mycobacterium bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

gamma/delta and other unconventional T lymphocytes: what do they see and what do they do?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Phosphoantigen presentation by macrophages to mycobacterium tuberculosis--reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Phenotypically Activated γδ T Lymphocytes in the Peripheral Blood of Patients with Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Recent findings in immunology give tuberculosis vaccines a new boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Isolation and partial characterisation of the Triton X-100 solubilised protein antigen from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Antigenic definition of plasma membrane proteins of Bacillus Calmette-Guérin: predominant activation of human T cells by low-molecular-mass integral proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette-Gúerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

TB subunit vaccines--putting the pieces together

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

A common pharmacophoric footprint for AIDS vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Virulence, immunity, and vaccine related to Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of Mycobacterium tuberculosis and M. bovis BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Isolation, purification and immunological characterization of novel low molecular weight protein antigen CFP 6 from culture filtrate of M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Human Th1 Cell Lines Recognize the Mycobacterium tuberculosis ESAT-6 Antigen and its Peptides in Association with Frequently Expressed HLA Class II Molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Identification of the new T-cell-stimulating antigens from Mycobacterium tuberculosis culture filtrate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Characterization of HLA-DR- and TCR-binding residues of an immunodominant and genetically permissive peptide of the 16-kDa protein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Detection of Active Tuberculosis Infection by T Cell Responses to Early‐Secreted Antigenic Target 6‐kDa Protein and Culture Filtrate Protein 10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Low molecular mass protein patterns in mycobacterial culture filtrates and purified protein derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Antigen specificity of T-cell response to Mycobacterium avium infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Innate IFN-gamma production in cattle in response to MPP14, a secreted protein from Mycobacterium avium subsp. Paratuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Delineation of Human Antibody Responses to Culture Filtrate Antigens ofMycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Comparative analysis of B- and T-cell epitopes of Mycobacterium leprae and Mycobacterium tuberculosis culture filtrate protein 10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Advances in tuberculosis vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The 19-kD antigen and protective immunity in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Toward the Quantitative Prediction of T-Cell Epitopes: CoMFA and CoMSIA Studies of Peptides with Affinity for the Class I MHC Molecule HLA-A*0201

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

T cell activation by lipopeptide antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Characterization of novel immunodominant antigens of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Molecular composition of the outermost capsular material of the tubercle bacillus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The outermost capsular arabinomannans and other mannoconjugates of virulent and avirulent tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Deficiency in mycolipenate- and mycosanoate-derived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Purification and characterization of three immunodominant proteins (38, 30, and 16 kDa) of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Serological distinction of integral plasma membrane proteins as a class of mycobacterial antigens and their relevance for human T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Immunoreactivity of peptides generated by limited proteolysis of 71-kDa cell wall protein of Mycobacterium tuberculosis H37Ra using PLG-microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Heat shock proteins and the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Crossreactivity of SLE autoantibodies with 70 kDa heat shock proteins of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Site-directed mutation on the only universally conserved residue Leu122 of small heat shock protein Hsp16.3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Lipoprotein antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Lipoproteins of Mycobacterium tuberculosis: an abundant and functionally diverse class of cell envelope components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Intranasal vaccination of mice against infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Improved tuberculosis DNA vaccines by formulation in cationic lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Cu,Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Generation of antibodies to the signal peptide of the MPT83 lipoprotein of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Homology between the MPB70 and MPB83 proteins of Mycobacterium bovis BCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1-->3)-mannobiose moieties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Analysis of post-translational modification of mycobacterial proteins using a cassette expression system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

ESAT-6 proteins: protective antigens and virulence factors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021

Evidence for glycosylation sites on the 45-kilodalton glycoprotein of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.014

7 January 2021